IRD Opus Genetics, Inc.
Financings ·
Purchasers paid $3.39 per share for 7,374,632 non-voting convertible preferred shares. Conversion into common stock depends on stockholder approval at the 2026 annual meeting. Preliminary cash was $45 million at year end.
The Nasdaq-listed company sold shares, warrants and pre-funded warrants through Craig-Hallum for gross proceeds of approximately $20.0 million. Its CEO and board chairman bought in a separate private placement.
Opus Genetics can sell up to $40,000,000 of stock through Leerink Partners, which takes 3.0% of gross proceeds. The company's last reported sale price was $1.42 on January 10, 2025, and the earlier JonesTrading program had sold about $26.4 million of stock.
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), along with other types of therapies for ophthalmic disorders. Its pipeline is a portfolio of seven adeno-associated virus (AAV)-based gene therapies designed as one-time treatments, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration. Other candidates target RHO, CNGB1, RDH12, NMNAT1 and MERTK. The most advanced program, OPGx-LCA5, is in a Phase 1/2 trial at the University of Pennsylvania. The company reported positive results from six late-stage participants in September 2025 and plans to present six-month pediatric cohort data at the ARVO conference in May 2026. The company also advances Phentolamine Ophthalmic Solution 0.75%, which is FDA-approved for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. Its gene therapies are administered by subretinal injection, and its programs draw on research from the University of Pennsylvania, Harvard Medical School and the University of Florida.
| Product or program | What it is | Stage |
|---|---|---|
| OPGx-LCA5 | AAV8 gene therapy delivering LCA5 gene for LCA5-related inherited retinal degeneration | Phase 1/2; RMAT and Orphan Drug designations granted |
| OPGx-BEST1 | AAV gene therapy for BEST1-related retinal degeneration | |
| Phentolamine Ophthalmic Solution 0.75% | Small-molecule therapy for pharmacologically induced mydriasis | FDA-approved |
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$49.6 million | -$57.5 million |
| Cash from operations | -$35.3 million | -$25.6 million |
| Cash and equivalents | $45.1 million | $30.3 million |
| Short-term investments | $0 | $2,000 |
Our latest story on this, dated Feb 19, 2026: "Opus Genetics closes private placement of Series B preferred stock for approximately $25.0 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 19, 2026: "Opus Genetics closes private placement of Series B preferred stock for approximately $25.0 million". The story links the filing or release it is based on. Read the story.
Opus Genetics, Inc. trades under the ticker IRD on NASDAQ.
Opus Genetics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:R3X1; LS:A2QG4Z.
The SEC Central Index Key (CIK) for Opus Genetics, Inc. is 1228627. Its filings are on SEC EDGAR.
83,195,823 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Opus Genetics, Inc. under United States.
Our directory classifies Opus Genetics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Opus Genetics, Inc. is US67577R1023.
aibio.space lists Opus Genetics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), along with other types of therapies for ophthalmic disorders. Its pipeline is a portfolio of seven adeno-associated virus (AAV)-based gene therapies designed as one-time treatments, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration.
OPGx-LCA5: AAV8 gene therapy delivering LCA5 gene for LCA5-related inherited retinal degeneration Stage: Phase 1/2; RMAT and Orphan Drug designations granted.
OPGx-BEST1: AAV gene therapy for BEST1-related retinal degeneration Stage: Not stated in the text.
Opus Genetics, Inc. reported a net loss of $49.6 million for the fiscal year ended Dec 31, 2025, and used $35.3 million of cash in operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,5.03,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio